These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24397178)

  • 1. [Management of elderly onset diabetes].
    Ouchi M; Nakano H
    Nihon Rinsho; 2013 Nov; 71(11):2025-9. PubMed ID: 24397178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes].
    Jojima T; Aso Y
    Nihon Rinsho; 2013 Nov; 71(11):1987-92. PubMed ID: 24397171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents].
    Mori Y
    Nihon Rinsho; 2011 Aug; 69(8):1505-14. PubMed ID: 21838054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
    Yamazaki K; Inoue T; Yasuda N; Sato Y; Nagakura T; Takenaka O; Clark R; Saeki T; Tanaka I
    J Pharmacol Sci; 2007 May; 104(1):29-38. PubMed ID: 17485917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
    Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
    Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of α-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease.
    Sawada T; Shiotani H; Terashita D; Nagasawa Y; Kim SS; Koide M; Yokoyama M
    Circ J; 2014; 78(1):248-55. PubMed ID: 24225338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cognitive decline in elderly individuals with type 2 diabetes mellitus].
    Sakurai T
    Nihon Rinsho; 2013 Nov; 71(11):1960-4. PubMed ID: 24397166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
    Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
    Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study.
    Kaku K; Katou M; Igeta M; Ohira T; Sano H
    Diabetes Obes Metab; 2015 Dec; 17(12):1198-201. PubMed ID: 26277887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vildagliptin with metformin once-daily regimen-insights from a single-center analysis.
    Chatterjee S; Chatterjee S
    Am J Ther; 2015; 22(3):195-8. PubMed ID: 23665884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Davis TME; Mulder H; Lokhnygina Y; Aschner P; Chuang LM; Raffo Grado CA; Standl E; Peterson ED; Holman RR;
    Diabetes Obes Metab; 2018 Jun; 20(6):1427-1434. PubMed ID: 29405540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
    Araki E; Tanizawa Y; Tanaka Y; Taniguchi A; Koiwai K; Kim G; Salsali A; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2015 Jul; 17(7):665-74. PubMed ID: 25772548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frailty and safety: the example of diabetes.
    Abbatecola AM; Olivieri F; Corsonello A; Strollo F; Fumagalli A; Lattanzio F
    Drug Saf; 2012 Jan; 35 Suppl 1():63-71. PubMed ID: 23446787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.
    Kadowaki T; Sarai N; Hirakawa T; Taki K; Iwasaki K; Urushihara H
    Diabetes Obes Metab; 2018 Dec; 20(12):2830-2839. PubMed ID: 29974673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
    Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
    J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database.
    Tanabe M; Motonaga R; Terawaki Y; Nomiyama T; Yanase T
    J Diabetes Investig; 2017 Mar; 8(2):227-234. PubMed ID: 27549920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K;
    Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoglycemic peptide-enriched hydrolysates of Corbicula fluminea and Chlorella sorokiniana possess synergistic hypoglycemic activity through inhibiting α-glucosidase and dipeptidyl peptidase-4 activity.
    Huang TH; Liu PY; Lin YL; Tsai JS
    J Sci Food Agric; 2022 Jan; 102(2):716-723. PubMed ID: 34171123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.